Nutrition Status of Adults With PKU Before and During Treatment With Pegvaliase
NCT03856203
Amino Acid Metabolism, Inborn Errors, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT Number: NCT02445521
The objective of this study is to test four home phenylalanine monitoring prototype devices, selected out of a pool of candidates by the National PKU Alliance Scientific Committee.
Looking for future studies?
Notify MeAll sexes
Observational
Children's Healthcare of Atlanta (CHOA), Atlanta, Georgia, United States
A real time, point-of-care and home phenylalanine monitoring system would provide patients with quick results and feedback. Home monitoring devices' phenylalanine measurements will be compared to the current gold-standard measurement of phenylalanine (plasma concentration) in four subjects with PKU and one control subject. The study will enroll subjects with different baseline phenylalanine concentrations (i.e., patients with poor to good metabolic control, assessed by comparing current phenylalanine concentrations to established treatment ranges).
For each prototype device, three separate measurements of phenylalanine per subject will be performed. Three prototype devices require whole blood, thus 1 teaspoon (approximately 4mL) of whole blood will be collected through venipuncture and blood spots will be used to conduct tests. One prototype requires capillary blood to be collected through a fingerstick, and will require three blood spots from the stick. A single plasma amino acid analysis for each participant will also be performed using leftover whole blood from the 4mL blood draw through quantitative ion exchange chromatography, reported as micromoles/L.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Day 1
Phenylalanine values for each of the three runs on each device for the same individual will be compared. Each PKU subject will be assessed separately to assess the reliability of each device since the subjects will have a range of phenylalanine concentrations.
Time frame: Day 1
Average phenylalanine values measured by the four tests of each device in each subject will be calculated. Mean concentrations for each device will be compared to the control (gold standard measure of plasma phenylalanine).
Emory University
Other
Testing of Four Home Phenylalanine Monitoring Prototype Devices Using Whole Blood From Normal and PKU Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03856203
Amino Acid Metabolism, Inborn Errors, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT05051657
Amino Acid Metabolism, Inborn Errors, Brain Diseases
Belfast, United Kingdom
View Trial DetailsNCT04679467
Amino Acid Metabolism, Inborn Errors, Brain Diseases
Bologna, Italy
View Trial DetailsNCT05487378
Amino Acid Metabolism, Inborn Errors, Brain Diseases
Birmingham, United Kingdom
View Trial Details